The CKM–GDM multi-organ precision model: reframing gestational diabetes as an early cardiovascular–kidney–metabolic event in Southeast Asia

Background Gestational diabetes mellitus (GDM) is amongst the commonest complications of pregnancy and an early marker of lifetime cardiovascular–kidney–metabolic (CKM) risk. Its burden is heavy in Southeast Asia, where prevalence ranges from about 8% to nearly 30% and a lean phenotype — with marked over-representation of the insulin-secretion-limited subtype — diverges from Western cohorts, yet its definition, timing, and treatment remain contested. Aim This clinically oriented narrative review synthesises the diagnostic landscape, the shift to early diagnosis, the vascular mechanism, and precision care, centred on Southeast Asia. Key themes Competing criteria (IADPSG one-step, WHO 2013, NICE, ADA two-step and the pragmatic Indian DIPSI test) identify different populations. The TOBOGM trial shows that early (pre-20-week) treatment improves outcomes, and first-trimester biomarkers—low adiponectin and sex-hormone-binding globulin, glycosylated fibronectin, atherogenic lipids, and multimarker or machine-learning panels including a non-fasting Asian-women panel—show potential to make early prediction feasible. Vascular and endothelial dysfunction (oxidative stress, eNOS uncoupling, sFlt-1/PlGF imbalance, and arterial stiffness) is proposed as the unifying early signal and a mechanistic bridge to later type 2 diabetes, cardiovascular disease, and chronic kidney disease. GDM is increasingly recognised as heterogeneous (insulin-resistant, insulin-deficient, and mixed subtypes), inviting subtype- and phenotype-guided precision diagnosis and treatment. Conclusion We propose that GDM may be productively reframed as an early, vascular, and potentially precisely treatable CKM event—screened early, matched to phenotype and linked to lifelong follow-up, and fitted to the epidemiology, genetics, and health systems of Southeast Asia. This reframing is a testable hypothesis that requires prospective validation before routine adoption.